Prospect: information for the user
Suxametonio Ethypharm 50mg/ml injectable solution and for perfusion EFG
chloride of suxamethonium dihydrate
Read this prospect carefully beforethey administer this medication to you, because it contains important information for you.
1.What is Suxametonio Ethypharm and for what it is used
2.What you need to know before they administer Suxametonio Ethypharm
3.How to administer Suxametonio Ethypharm
4.Possible adverse effects
5.Storage of Suxametonio Ethypharm
6.Contents of the package and additional information
SuxametonioEthypharmcontains a medicine called suxamethonium chloride. It belongs to a group of medicines called muscle relaxants.
SuxametonioEthypharmis used:
Consult your doctor if you want a more detailed explanation of this medicine.
Do not administerSuxametonio Ethypharm:
Warnings and precautions
A qualified anesthesiologist will administer this medication, along with other medications to help you sleep. A ventilation device will be used to help you breathe.
Consult your doctor, nurse, or operating room staff before receiving this medication if:
Children
Special attention or additional monitoring should be given to infants and children receiving suxamethonium. If any of the above points apply to you or your child, consult your doctor.
Use of Suxametonio Ethypharm with other medications
Inform your doctor, nurse, or other relevant hospital staff if you are taking or have recently taken any other medication
Inform your doctor if you have recently been exposed to pesticides, p.eg., sheep dips.
Inform your doctor if you have recently received a blood transfusion.
If you have any doubts about whether you should receive this medication, consult your doctor or nurse.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or think you may be pregnant, or plan to become pregnant, consult your doctor before receiving this medication.
Driving and operating machinery
Do not drive or operate machinery immediately after surgery because it may be hazardous. Your doctor will tell you how long you should wait before driving and operating machinery.
You will receiveSuxamethonium Ethypharmas an injection into a vein (intravenously).
Your doctor will decide on the appropriate dose and treatment duration for your procedure, which will depend on:
Suxamethonium Ethypharmwill be administered in carefully controlled conditions. If you have any other questions about the use of this medication, consult your doctor.
Adults, elderly patients, and adolescents over 12years
By intravenous injection:
1mg per kilogram of body weight.
Administration of supplementary doses of 50% to 100% of the initial dose, administered at intervals of 5 to 10minutes, will maintain muscle relaxation.
By intravenous infusion (drip):
Solution at 0.1-0.2%, at a rate of 2.5 to 4mg per minute.
The maximum total dose is 500mg.
Childrenfrom 1 to 12years
By intravenous injection:
1-2mg per kilogram of body weight.
Infants (less than 1year): 2mg per kilogram of body weight.
If you are given too much Suxamethonium Ethypharm
Since this medication will be administered in a hospital, it is unlikely that you will receive an excessive or insufficient dose; however, inform your doctor or nurse if you have any doubts.
Like all medications, suxamethonium chloride for injection or infusion may cause side effects, although not everyone will experience them. If you experience any type of side effect, consult your doctor, nurse, or other relevant hospital staff member, even if it is a side effect that does not appear in this prospectus.
In very rare cases, a sudden and severe allergic reaction to suxamethonium chloride may occur. If you experience any of the following symptoms, inform your doctor or nurse immediately:
There are other serious side effects that you and your doctor should monitor.
You must inform your doctor or nurse immediately if you experience any of the following symptoms:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Rare (may affect up to 1 in 1,000 people)
Very rare (may affect up to 1 in 10,000 people)
Other side effects include:
Unknown frequency: cannot be estimated from available data
Reporting side effects
If you experience any type of side effect, consult your doctor, nurse, or pharmacist, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for Pharmacovigilance of Medicinal Products for Human Use:https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medication.
Keep this medication out of the sight and reach of children.
This medication should not be administered with suxamethonium chloride injection or for infusion after the expiration date appearing on the box and ampoule label after CAD. The doctor or nurse will verify that the expiration date has not been exceeded before administering the injection. The expiration date is the last day of the month indicated.
Store in refrigerator (between 2°C and 8°C). Do not freeze.
Store in the original packaging to protect it from light.
Once opened, this medication must be used immediately.
Do not use this medication if you observe any change in color or if it contains particles.
Medications should not be disposed of through drains or in the trash. Your doctor or nurse will dispose of the medications that you no longer need. These measures will help protect the environment.
Composition of Suxamethonium Ethypharm
The active principle is dihydrate suxamethonium chloride50mg/ml.
The othercomponentsare hydrochloric acid (to adjust the pH) and water for injectable preparations.
Appearance of the product and contents of the package
Suxamethonium chloride injectable or for perfusion is a transparent and colorless solution supplied in a transparent glass vial of 2ml. Each vial of 2ml contains 100mg of dihydrate suxamethonium chloride (equivalent to 73.1mg of suxamethonium). Each boxcontains10vials.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
Ethypharm
194 Bureaux de la Colline, Building D
92213 Saint- Cloud CEDEX
France
Responsible for manufacturing:
Macarthys Laboratories Limited t/a Martindale Pharma
Bampton Road, Harold Hill,
Romford, Essex RM3 8UG
United Kingdom
O
ETHYPHARM,
Chemin de la Poudriere, GRAND QUEVILLY,
76120,France
O
ETHYPHARM,
Zone Industrielle de Saint-Arnoult,
CHATEAUNEUF EN THYMERAIS, 28170,France
Ó
Fannin Limited,
Fannin House,
South County Business Park,
Dublin 18, D18 Y0C9,
Ireland
Last review date of this leaflet:March 2020
The detailed and updated information of this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
This information is intended solely for healthcare professionals:
Suxamethonium Ethypharm50mg/ml injectable solutionand for perfusion EFGis used for muscle relaxation during general anesthesia.
By intravenous injection
Adults and adolescents over 12years
The dose depends on body weight, the degree of muscle relaxation required, the route of administration, and the individual patient's response.
To achieve endotracheal intubation, suxamethonium chloride is normally administered by intravenous injection at a dose of 1mg/kg. With this dose, muscle relaxation will generally be achieved in 30 to 60seconds and will last for 2 to 6minutes. Higher doses will produce longer-lasting muscle relaxation, but doubling the dose does not necessarily mean that the duration of relaxation will be doubled. Administration of supplementary doses of suxamethonium chloride at 50%, 75%, or 100%, at intervals of 5 to 10minutes, will maintain muscle relaxation during short surgical procedures performed under general anesthesia.
The total dose of suxamethonium chloride should not exceed 500mg.
Newborns and small children are more resistant to suxamethonium than adults.
Children aged 1 to 12years
1-2mg/kg by intravenous injection.
Newborns, less than 1year
2mg/kg by intravenous injection.
By intravenous perfusion
Suxamethonium chloride can be administered by intravenous perfusion as a solution of 0.1-0.2%, diluted in 5% glucose solution or isotonic saline solution, at a rate of 2.5 to 4mg per minute. The perfusion rate should be adjusted according to the individual patient's response.
Older adults
The same as adults.
Older adults may be more susceptible to cardiac arrhythmias, especially if they are also taking digitalis medications (seesection4.4).
By intravenous bolus or perfusion.
The use of neostigmine and other cholinesterase inhibitors should be avoided, as they prolong the depolarizing effect of suxamethonium chloride.
The decision to use neostigmine to reverse the phase II block induced by suxamethonium depends on the individual case and the medical judgment. Monitoring of neuromuscular function will provide valuable information for this decision. If neostigmine is used, its administration should be accompanied by appropriate doses of an anticholinergic such as atropine.
This medicine should not be mixed with other medicinesexcept those mentioned inSpecial precautions for disposal and other manipulations.
Suxamethonium Ethypharm is an acidic substance and should not be mixed with solutions with a high degree of alkalinity, such as barbiturates.
Use once and eliminate any remaining solution.
Suxamethonium chloride can be administered by intravenous perfusion as a solution of 0.1-0.2%, diluted in 5% glucose solution or isotonic saline solution, at a rate of 2.5 to 4mg per minute. The perfusion rate should be adjusted according to the individual patient's response.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.